Table 1.
Human neurological diseases and/or syndromes associated with ‘long COVID’; recent reports of age-related, progressive, terminal and/or incapacitating neurological disorders associated with SARS-CoV-2 infection and COVID-19; the majority of these most recent reports involve COVID-19 with the neurodegenerative disorders AD, PrD (primarily Creutzfeldt-Jakob disease; CJD); and/or the onset of visual system disturbances (alphabetically ordered; Hill et al., 2021; Hixon et al., 2021; Oldfield et al., 2021; Zhou et al., 2021; Ahmad et al., 2022; Baazaoui and Iqbal, 2022; Flud et al., 2022; Lukiw, 2022; Piekut et al., 2022; Piras et al., 2022; Visco et al., 2022).
| Neurological disorder | Reference |
|---|---|
| Alzheimer's disease (AD) | Hill et al., 2021 |
| Chiricosta et al., 2021 | |
| Ciaccio et al., 2021 | |
| Ding et al., 2021 | |
| Zhao et al., 2021 | |
| Shen et al., 2022 | |
| Zhao and Lukiw, 2022 | |
| Epilepsy | Roy et al., 2021 |
| Multiple sclerosis (MS) | Muñoz-Jurado et al., 2022 |
| Prion disease (PrD) | Bernardini et al., 2022 |
| Ciolac et al., 2021 | |
| Kuvandik et al., 2021 | |
| Lukiw et al., 2022 | |
| Olivo et al., 2022 | |
| Shahzad and Willcox, 2022 | |
| Szabo et al., 2022 | |
| Tayyebi et al., 2022 | |
| Tetz and Tetz, 2022 | |
| Young et al., 2020 | |
| Visual system disturbances | Hill et al., 2021 |
| Hixon et al., 2021 | |
| Tisdale et al., 2021 | |
| Zhao et al., 2021 | |
| Lukiw, 2022 | |
| Piras et al., 2022 |